Cargando…
Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
Before a medicine can be recommended for a marketing authorization research must be provided to regulators that convincingly supports the benefit‐risk of the product in the claimed indication. The established criteria for such research are usually expressed in terms of evidence from randomized contr...
Autores principales: | Slattery, Jim, Kurz, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687174/ https://www.ncbi.nlm.nih.gov/pubmed/32301230 http://dx.doi.org/10.1002/pds.5005 |
Ejemplares similares
-
What do we still need to learn on digitally assessed biomarkers?
por: Acs, Balazs, et al.
Publicado: (2021) -
Commentary: Extracorporeal membrane oxygenation for patients with refractory Coronavirus Disease 2019 (COVID-19): What do we know and what do we need to learn?
por: Jacobs, Jeffrey P., et al.
Publicado: (2022) -
Pregnant adolescents living with HIV: what we know, what we need to know, where we need to go
por: Callahan, Tegan, et al.
Publicado: (2017) -
Sodium and brain injury: do we know what we are doing?
por: Zygun, David A
Publicado: (2009) -
Understanding the lingering consequences of what we treat and what we do
por: Angus, Derek C
Publicado: (2004)